RNA binding protein‐directed control of leukemic stem cell evolution and function

• Published in: HemaSphere Vol. 8; no. 8; pp. e116 - n/a
• Main Authors: Joshi, Pratik, Keyvani Chahi, Ava, Liu, Lina, Moreira, Steven, Vujovic, Ana, Hope, Kristin J.
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.08.2024; Wiley
• Subjects: Hematopoiesis; Review
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1002/hem3.116

Strict control over hematopoietic stem cell decision making is essential for healthy life‐long blood production and underpins the origins of hematopoietic diseases. Acute myeloid leukemia (AML) in particular is a devastating hematopoietic malignancy that arises from the clonal evolution of disease‐initiating primitive cells which acquire compounding genetic changes over time and culminate in the generation of leukemic stem cells (LSCs). Understanding the molecular underpinnings of these driver cells throughout their development will be instrumental in the interception of leukemia, the enabling of effective treatment of pre‐leukemic conditions, as well as the development of strategies to target frank AML disease. To this point, a number of precancerous myeloid disorders and age‐related alterations are proving as instructive models to gain insights into the initiation of LSCs. Here, we explore this myeloid dysregulation at the level of post–transcriptional control, where RNA‐binding proteins (RBPs) function as core effectors. Through regulating the interplay of a myriad of RNA metabolic processes, RBPs orchestrate transcript fates to govern gene expression in health and disease. We describe the expanding appreciation of the role of RBPs and their post–transcriptional networks in sustaining healthy hematopoiesis and their dysregulation in the pathogenesis of clonal myeloid disorders and AML, with a particular emphasis on findings described in human stem cells. Lastly, we discuss key breakthroughs that highlight RBPs and post–transcriptional control as actionable targets for precision therapy of AML.